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Abstract: Eisenmenger syndrome is the most severe form of pulmonary arterial hypertension and arises on the basis of 
congenital heart disease with a systemic-to-pulmonary shunt. Due to the chronic slow progressive hypoxemia with central 
cyanosis, adult patients with the Eisenmenger syndrome suffer from a complex and multisystemic disorder including co-
agulation disorders (bleeding complications and paradoxical embolisms), renal dysfunction, hypertrophic osteoarthropa-
thy, heart failure, reduced quality of life and premature death. 
For a long time, therapy has been limited to symptomatic options or lung or combined heart-lung transplantation. As new 
selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arte-
rial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deteriora-
tion also in Eisenmenger patients. Unfortunately, data in Eisenmenger patients suffer from small patient numbers and a 
lack of randomized controlled studies. 
To optimize the quality of life and the outcome, referral of Eisenmenger patients to spezialized centers is required. In such 
centers, specific interdisciplinary management strategies of physicians specialized on congenital heart diseases and PAH 
should be warranted.  
This medical update emphasizes the current diagnostic and therapeutic options for Eisenmenger patients with particularly 
focussing on specific management and surgical aspects. 
Keywords: Cardiovascular diseases, adult congenital heart defects, pulmonary hypertension, Eisenmenger syndrome, follow-
up studies, Competence Network for Congenital Heart Defects. 
SPECIFIC MANAGEMENT ASPECTS 
1.1. Erythrocytosis - Phlebotomy 
 Secondary  erythrocytosis due to increased erythro-
poietin production is a physiologic, adaptive response to 
chronic hypoxemia and is the appropriate term to describe 
the increased mass of red blood cells. Polycythemia is a 
completely inappropriate term as it describes a malignant 
clonal stem cell disorder of all three cell lines - including red 
blood cells, white blood cell and platelets. This is in contrast 
to patients with Eisenmenger syndrome (ES) who have even 
a decreased amount of platelets.  
  There is an inverse relationship between cyanosis (oxy-
gen saturation) and red blood cell count: the lower the oxy-
gen saturation, the higher the red blood cell count and the 
hematocrit in iron replete patients [1]. There is a direct   
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relationship between red blood cell mass and exercise capac-
ity despite higher blood viscosity [2].  
  Blood viscosity depends on many factors: red blood cell 
mass and morphology, aggregation and dispersion of blood 
cells, plasma viscosity, temperature and shear stress [2-4]. 
Secondary erythrocytosis results in increased shear stress, 
which modifies the balance between vasodilators and vaso-
constrictors. Cyanosis and secondary erythrocytosis affect 
the pulmonary and systemic vascular system. Severe sys-
temic endothelial dysfunction is evident in patients with cya-
notic CHD as evidenced by the striking impairment of endo-
thelium-dependent vasodilation induced by acetylcholine [5]. 
It is not clear whether these findings are clinically relevant, 
but it is conceivable that severe endothelial vasodilator dys-
function may be involved in the development of cardiovas-
cular events in Eisenmenger patients [5].  
  Compensated secondary erythrocytosis (stable hemoglo-
bin in an iron-replete state) represents an appropriate, adap-
tive response to chronic hypoxemia. Hyperviscosity symp-
toms are absent, mild or moderate even at hematocrit levels 
higher than 70%. Patients with decompensated erythrocyto-364    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Oechslin et al. 
sis have failed to establish an equilibrium and complain of 
moderate to severe hyperviscosity symptoms [6-9].  
  Systematic assessment of hyperviscosity symptoms at 
each clinical visit is essential and allows a precise clinical 
follow-up and early detection of clinical deterioration (Table 
1) [9].  
  There is an ongoing debate whether iron deficiency 
causes or contributes to symptoms, whole blood hypervis-
cosity and risk of stroke. Indeed, there are controversial data 
if iron deficiency impacts whole blood hyperviscosity [10-
16]. A recent study showed that iron deficiency did not alter 
blood viscosity [2]. However, there are several limitations of 
such an in vitro study as simplified steady state models are 
used to measure infinitely more complex and dynamic sys-
tems in vivo and the data may not apply to in vivo conditions. 
  Iron deficiency may cause headache, reduced exercise 
tolerance, restless leg syndrome [17, 18]. Despite the dis-
crepancy of data and ongoing controversy, iron deficiency 
must be avoided in patients with ES. A patient in an iron-
deplete state cannot produce hemoglobin at a level adequate 
and appropriate to the severity of cyanosis (the lower the 
oxygen saturation, the higher the hemoglobin). 
Indications for Phlebotomy 
  Prophylactic or routine phlebotomies to maintain the he-
matocrit level within an arbitrary level and for the prevention 
of cerebrovascular events are not justified [4, 8, 9, 19, 20]. 
Unfortunately, repeat, injudicious phlebotomies are still per-
formed in daily practice. This practice must be discouraged 
because it causes iron deficiency, reduced exercise tolerance, 
impaired oxygen transport capacity due to anemia and in-
Table 1.  Clinical Assessment of Patients with Cyanotic Congenital Heart Disease 
 Name: ....................................................  Date of Birth: …..…/……../19.................  Clinic Visit Date: …..…/……../20….. 
Presence and Severity of Hyperviscosity Symptoms (Secondary Erythrocytosis!) 
0 Absent  Does not bother  2 Moderate  Interferes with some but not most activities 
1 Mild  Bothers without interfering with normal activities  3 Severe  Interes with most or all activities 
 
 Hyperviscosity  Symptoms  Absent 
0 
Mild 
1 
Moderate 
2 
Severe 
3 
Headache        
Faintness, dizziness, lightheadedness         
Slow mentation, impaired alertness, irritability, a sense of dis-
tance or dissociation 
     
Visual disturbances (blurred or double vision), scotoma         
Paresthesias of fingers, toes, or lips         
Tinnitus        
Fatigue, lassitude, lethargy         
Myalgias muscle weakness, anorexia         
Erythrocytosis 
Restless legs         
Bleeding and Ischemic Events 
Hemorrhagic  Easy bruising (fragile skin)         
Diathesis  Gingival bleeding (fragile gums)         
(not requiring  Hemoptysis         
medical atten- Epistaxis        
  Menorrhagia (menstruation lasting more than 7 days)         
   No Yes  (specify) 
Major Bleed- Hemoptysis    
(requiring  Traumatic bleeding (accidental injury, surgery)     
attention) Others     
Ischemic  Stroke / Transient Ischemic Attack (TIA)     
 Others     
Phlebotomy since last visit?       Yes (…….)   No  Iron supplements or vitamins containing iron?    Yes   No  
Aspirin?      Yes      No  Anticoagulants?      Yes (specify:…….…….)  No 
Annual Flu Shot?     Yes     No  Pneumovax?          Yes (Date: .……  …......)  No Eisenmenger Syndrome in Adults  Current Cardiology Reviews, 2010, Vol. 6, No. 4    365 
creased risk of cerebrovascular events [1, 2, 21]. Hemoglo-
bin levels that are physiologic for an acyanotic patient are 
misinterpreted to be adequate for cyanotic patients although 
relative iron-deficiency anemia is present. Relative iron defi-
ciency anemia is often ignored or not recognized in cyanotic 
patients as the hemoglobin may be less than 15 g/dl but 
should be greater than 18 g/dl [9]. Severity of secondary 
erythrocytosis per se is not a risk factor for stroke [21, 22]. 
Thus, an increased hemoglobin level, in and of itself, is no 
indication for phlebotomies and poses the potential hazards 
of iron deficiency. The primary goal of phlebotomy is to 
relieve temporarily moderate to severe hyperviscosity symp-
toms. Therapeutic phlebotomy is restricted to patients with 
moderate to severe hyperviscosity symptoms in the absence 
of both volume depletion and iron deficiency (Table 2).  
Table 2.  Management of Hyperviscosity Symptoms 
  Volume depletion  Volume replacement; 
  Iron deficiency (anemia)  Iron replacement; 
  Moderate to severe symptoms due to secondary erythrocytosis  
 phlebotomy and withdrawal of 300-500 cc of whole blood. 
 
There are two indications for phlebotomies: 
1)  moderate to severe hyperviscosity symptoms due to sec-
ondary erythrocytosis; 
2)  preoperative phlebotomy for autologous blood donation 
if the hematocrit level is above 65%. 
  Hyperviscosity will disappear after adequate phlebotomy 
within 24 hours resulting in increased cardiac output and 
systemic blood flow due to decreased whole blood viscosity 
and decreased systemic vascular resistance [23, 24]. 
Phlebotomy Procedure 
Phlebotomy can be a safe procedure, if the following safety 
measures are followed: 
a). Assessment of baseline vital signs and every 15 minutes 
for the 1
st hour after the procedure (more frequently if 
the patient is symptomatic); 
b). Insertion of bilateral intravenous lines allowing fluid re-
placement and phlebotomy;  
c). Some centers recommend air filters to avoid air embo-
lism; 
d). Preceding or concurrent infusion of 750 to 1000 cc of 
isotonic saline (at least over 1 hour) while phlebotomiz-
ing 500 cc of blood; 
e). Stop the procedure if the patient experiences severe hy-
potension, symptomatic palpitations, or pre-syncope/ 
syncope. 
Volume depletion or brain abscess must be strongly consid-
ered, if hyperviscosity symptoms (headache!) persist or do 
not improve after phlebotomy. A brain abscess may be ini-
tially missed and interpreted as hyperviscosity symptom. If 
hyperviscosity symptoms persist in the absence of volume 
depletion and abscess, a second phlebotomy performed 
within 48 hours may improve the symptoms. 
1.2. Hemostatic Abnormalities / Thrombosis / Paradoxi-
cal Embolism 
1.2.1. Hemostatic Abnormalities 
Hemostatic abnormalities are common and complex in cya-
notic patients. They are attributed to abnormalities in plate-
lets, coagulation pathways and other coagulation mecha-
nisms.  
  Platelets: platelet abnormalities include both thrombo-
cytopenia and thrombasthenia. There is a positive corre-
lation between platelet count and oxygen saturation or 
an inverse relationship with hemoglobin/ hematocrit 
level. Platelet counts are usually in the lower range of 
normal or reduced due to decreased production because 
of ineffective thrombopoiesis [25]. In addition, platelet 
survival is reduced [26], and platelet function measured 
by whole blood impedance aggregometry is decreased 
in patients with elevated hematocrit.
1  
  Abnormal coagulation parameters: Vitamin K depend-
ent clotting factors (factors II, VII, IX, X) and factor V 
are reduced. Increased fibrinolytic activity and depletion 
of the largest von Willebrand multimers contribute to 
the bleeding tendency in these patients [27, 28]. In this 
process, cyanosis, pulmonary vascular disease, and tur-
bulent blood flow are major determinants of the von 
Willebrand abnormality, which appears to be acquired 
and may contribute to the bleeding diathesis [7]. Bleed-
ing time fails to demonstrate hemostatic abnormalities 
as it is paradoxically shorter in cyanotic patients than in 
controls even though platelet counts/ function and co-
agulation parameters are abnormal. High blood viscosity 
resulting in impaired blood flow may explain this ob-
servation. 
  Vascular factors: Surgical observations have suggested 
increased tissue vascularity in ES patients. Endothelial 
derived nitric oxide and other vasodilators are released 
by the increased shear stress and results in arteriolar 
dilatation. By contrast, blood flow in the forearm was 
lower in cyanotic patients than in healthy subjects [5]. 
1.2.2. Bleeding and Thrombotic Diathesis 
  There is a paradox invoking a therapeutic dilemma: pa-
tients with ES are at risk for both bleeding and thrombosis. 
The coagulation abnormalities increase the risk of spontane-
ous bleeding, which is usually mild, self-limited and not 
life-threatening in Eisenmenger patients (Table 1). The use 
of a toothbrush with soft bristles and gentle brushing help to 
avoid or minimize gingival bleeding. 
 Hemoptysis (which is discussed below) is the most 
common and life-threatening bleeding complication, the   
others are less common [29, 30]. A multidisciplinary team 
including coagulation experts and other specialists can best 
manage major hemorrhage and the risk of serious morbidity 
and mortality [8]. 
 Thrombosis is facilitated by many factors: coagulation 
abnormalities, stasis of blood in the dilated flow chambers 
                                                             
1 Braun S, Mebus S, Eicken A, Hager A, Hess J, Kaemmerer H. Coagulation parameter 
and platelet function in whole blood samples of adults with cyanotic congenital cardiac 
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and vessels, atherosclerosis and/ or endothelial injury, the 
presence of thrombotic material (e.g. artificial valves, con-
duits), arrhythmias (atrial flutter/ atrial fibrillation). Interest-
ingly, the hemostatic abnormalities do not protect against 
blood clot formation. Laminated thrombi in the large, par-
tially calcified, and aneurysmal pulmonary arteries are com-
mon and occur in up to 30% of ES patients [29, 31-33], Fig. 
(1). 
  In situ thrombi can be the source of artery-to-artery in-
trapulmonary emboli resulting in pulmonary infarction and 
intrapulmonary hemorrhage. Female gender and low oxygen 
saturation were identified as risk factors for thrombus forma-
tion in the proximal pulmonary arteries [32]. This is in con-
trast to another study, where in situ thrombosis in pulmonary 
arteries were related to older age, biventricular dysfunction, 
poor functional class (NYHA class III and IV) and dilatation 
of pulmonary arteries and concomitant slow pulmonary 
blood flow. The degree of cyanosis or coagulation abnor-
malities did not differ between patients with and without 
thrombus formation in the central pulmonary arteries [33]. 
The occurrence or absence of thrombus does not seem to 
have an impact on survival [30].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1): Aneurysm of the pulmonary trunk with a deviation of the 
ascending aorta. 
 
  The key question remains: can long-term anticoagulation 
prevent thrombus formation in the central pulmonary artery 
and is there any benefit or hazard to Eisenmenger patients? 
Thrombus formation and bleeding coexist in patients with 
ES. There are no clinical data (see also Part II “1.1 Antico-
agulation”) to show effectiveness and benefit of routine anti-
coagulation or aspirin therapy in this population in the ab-
sence of any other strong indication (e.g. persistent atrial 
fibrillation/ flutter). Anticoagulation may be offered to pa-
tients with thrombus material in the central pulmonary artery 
or in case of pulmonary artery-to-pulmonary artery embo-
lism. However, meticulous monitoring and adjustment of the 
amount of sodium citrate in the test tubes is needed if an 
Eisenmenger patient is on anticoagulants. Although antico-
agulation has been shown to reduce morbidity and mortality 
in patients with idiopathic PAH it is tempting to draw similar 
conclusions for adults with ES. However, there are no data to 
support this approach and recommendations for routine anti-
coagulation cannot be given to patients with ES [20]. 
Risk Reduction Strategies 
  The risk of anticoagulation must be carefully assessed as 
both prophylactic and therapeutic anticoagulation reinforces 
hemostatic abnormalities [8]. 
a) Strategies to reduce the risk of bleeding include: 
  Limitation of anticoagulation to urgent indications for 
anticoagulation such as atrial fibrillation, recurrent 
thromboembolic events, mechanical heart valve pros-
theses prostheses; 
  Meticulous surveillance of anticoagulation; the optimal 
range of the INR or aPTT has not been evaluated. Rec-
ommendations for therapeutic anticoagulation are a tar-
get INR between 2.0 and 2.5 (in the absence of a me-
chanical valve) or a therapeutic aPTT of 1.5 times of the 
normal value; 
  Prompt therapy of respiratory tract infections. 
b) Strategies to reduce the risk of ischemic events include: 
  Avoidance and treatment of volume depletion; 
  Iron supplementation in patients with iron deficiency or 
those undergoing repeated phlebotomies; 
  Use of air filters in all intravenous lines. 
1.2.3. Paradoxical Emboli 
  Patient with ES are at risk for paradoxical emboli as there 
is a usually wide communication between the pulmonary and 
systemic circulation. Intravenous pacemaker or ICD systems 
are contraindicated as transvenous leads are associated with 
a 2-fold increased risk of systemic thromboemboli in patients 
with intracardiac shunts [34].  
Risk reduction strategies to reduce morbidity and mortality 
include: 
  Relative contraindication of intravenous implantation of 
pacemaker or ICD; 
  Air filters in all intravenous lines to prevent air embo-
lism. 
1.3. Cerebrovascular Events 
  Patients with ES have an increased risk of cerebrovascu-
lar events which is reported to occur in up to 14% of patients 
[21]. The causes of cerebrovascular events can be multifacto-
rial: paradoxical emboli, rheological problems, e.g. microcy-
tosis, and “traditional” risk factors, like hypertension and 
atrial fibrillation, are believed to contribute to this increased 
risk. Severe endothelial dysfunction may also be involved in 
the development of cardiovascular events in patients with 
cyanotic CHD as abnormal vascular regulatory mechanisms 
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tions; nitric oxide is not only a potent vasodilator but also a 
powerful antiaggregatory agent [5, 35]. 
  The misconception of secondary erythrocytosis being a 
risk factor for cerebrovascular events has been clarified: the 
severity of secondary erythrocytosis per se is not a risk fac-
tor [21, 22, 30]. Microcytosis caused by iron deficiency, usu-
ally due to repeated, inappropriate phlebotomies, was the 
strongest independent predictor for cerebrovascular events 
[21].  
Risk Reduction Strategy 
  Avoidance and treatment of volume depletion; 
  Air filters in all intravenous lines to prevent air embo-
lism; 
  Iron supplementation in patients being iron deficient or 
subjected to recurrent phlebotomy. 
1.4. Renal Dysfunction 
  Renal dysfunction affects two thirds of adults with ES 
and has a strong impact on mortality in patients with at least 
moderate renal dysfunction (Glomerular Filtration Rate < 60 
mL min
-1 1.73 m
-2) [36]. Both functional and structural ab-
normalities of the kidneys occur in patients with cyanotic 
congenital disease and the underlying mechanisms leading 
renal impairment are multifactorial and complex and are still 
a matter of debate [4, 37]. Volume depletion and/ or admini-
stration of nonsteroidal anti-inflammatory drugs can be fatal. 
Thus, routine assessment of kidney function is recommended 
not only for those on nephrotoxic drugs, but for all Eisen-
menger patients to obtain prognostic information (Table 3). 
1.5. Hemoptysis 
  This life-threatening complication is common in patients 
with ES and reported in up to 100% [30, 38, 39]. Rupture of 
aortopulmonary collaterals or of an aneurysm of the pulmo-
nary artery is usually fatal, Fig. (1). 
  Fortunately, hemoptysis is not a common mode of death 
[38-40]. Hemoptysis is an external manifestation of an in-
trapulmonary hemorrhage and does not reflect the extent of 
bleeding. Major hemoptysis requires evaluation by a 
multidisciplinary team.  
General diagnostic and therapeutic aspects include [8]: 
  Hospital admission; 
  Reduction of physical activity and suppression of non-
productive cough; 
  Chest x-ray followed by thoracic computed tomography 
if there are infiltrates on the chest x-ray, in order to as-
sess the severity of intrapulmonary bleeding or to visual-
ize in situ thromboses in the proximal dilated pulmonary 
arteries; 
  Avoidance of bronchoscopy as it rarely provides useful 
information, but it confers risks. Bronchoscopy may be 
performed by an expert team including anesthetists to 
identify the location of bleeding if the location/ source of 
the bleeding is unclear and subsequent angiography and 
coil occlusion of the collateral vessels are considered; 
  Immediate discontinuation of aspirin, nonsteroidal anti-
inflammatory drugs and oral anticoagulants;  
  Treatment of hypovolemia and anemia. Hemoglobin 
must be adequate to the degree of cyanosis! 
Specific diagnostic/ therapeutic aspects may be needed, if 
hemoptysis is severe or incessant: 
  Consider administration of platelets in the presence of 
low platelet counts and/ or administration of fresh fro-
zen plasma, vitamin K or coagulation factors; 
  Angiography with selective embolization of the artery 
supplying the source of blood loss; 
  Sputum culture and treatment of infectious disease. 
Consider tuberculosis as a cause of hemoptysis. 
Risk reduction strategy: 
  Immediate treatment of respiratory tract infections; 
  Pneumovax and annual flu shot to prevent respiratory 
tract and pulmonary infections. 
1.6. Gout 
  Increased uric acid levels (hyperuricemia) are common in 
patients with cyanotic CHD and result from increased pro-
duction and decreased renal clearance [41]. In adults, renal 
hypoperfusion reinforced by a high filtration fraction en-
hances urate reabsorption and secondary hyperuricemia [41]. 
In contrast to primary hyperuricemia, secondary hyperurice-
mia seems to have little or no deleterious effect on renal 
function as soft tissue deposits are the exception in cyanotic 
patients [42].  
  Serum uric acid increases in proportion to hemodynamic 
severity in adults with ES and is independently associated 
with long term mortality [43]. Routine assessment of serum 
uric acid is inexpensive and may serve as an indicator for 
disease severity during follow-up (Table 3). 
  Clinical presentation of primary and secondary gout is 
similar, but acute gouty arthritis is less prevalent in adults 
with ES [41, 42].  
  Asymptomatic, secondary hyperuricemia is no indication 
for routine therapy to lower uric acid level because it does 
not have any serious impact on renal function. However, 
acute gouty arthritis, a very painful complication, responds 
well to oral or intravenous colchicine. Intravenous   
administration may be preferred during the acute phase to 
obviate the gastro-intestinal side effects (nausea, vomiting, 
diarrhea, volume depletion). This effective therapeutic 
measure may be continued with a low oral dose of colchicine 
to prevent recurrent episodes. Intraarticular administration of 
corticosteroids may be needed in selected patients (e.g. acute 
gouty arthritis of the knees). 
  Uricosuric agents (e.g. probenecid) or uricostatic agents 
(e.g. allopurinol) are treatment options in patients with recur-
rent gouty arthritis. Gouty arthritis may be triggered by diu-
retics, which interact with tubular excretion of urate. 
1.7. Cholelithiasis 
  Patients with cyanotic CHD have an increased turnover 
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concentration of unconjungated bilirubin in the bile. Thus, 
Eisenmenger patients are at risk for calcium bilirubinate 
gallstones complicated by acute cholecystitis. This serious, 
life-threatening complication can be further complicated by 
bacteremia (gram-negative sepsis) and endocarditis.  
  Patients with an acute cholecystitis must be referred to a 
tertiary care center where a multidisciplinary team with ex-
pertise in the management of these patients can provide the 
best care. An endoscopic retrograde cholangiography and 
papillotomy are attractive in the presence of a retained stone 
in the common bile duct to avoid general anesthesia and 
laparotomy with all their implications. However, care sup-
port by an anesthetist with special expertise in the manage-
ment of patients with PAH is advisable during this proce-
dure. Cholecystectomy must be considered and is best man-
aged by a multidisciplinary team in a tertiary center with an 
established adult CHD program. 
1.8. Hypertrophic Osteoarthropathy (HOA) 
  Patients with the ES often suffer from arthralgias, typi-
cally from of the knees and ankles. These arthralgias are 
often a manifestation of hypertrophic osteoarthropathy. 
  HOA is characterized by local cell proliferation and new 
osseous formation and periostitis, occuring particularly in the 
metacarpal, metatarsal, and long bones of the forearms and 
legs [42]. The exact etiology of HOA is unknown. However, 
HOA is often associated with right-to-left shunt lesions by-
passing the pulmonary circulation, or with an intrapulmonary 
shunting of blood. Presumably, factors or mediators in the 
systemic venous circulation that normally are removed or 
inactivated in the lung, are causative for HOA, as they es-
cape an inactivation in the pulmonary capillary bed due to 
the right-to-left shunt. Due to the right-to-left shunt, mega-
karyocytes can reach the bones via the systemic circulation 
without fragmentation in the pulmonary microvasculature. 
They may activate local endothelial cells through the release 
of platelet-derived growth factor, initiating clubbing. For 
treatment Salsalate, an nonacetylated analog of aspirin, or 
oral corticosteroids may be used, while nonsteroidal anti-
inflammatory agents should be avoided.  
1.9. Travel to High Altitude / Air Flight 
  Traveling is an important life quality factor for many 
patients. However, the safety of traveling in a commercial 
aircraft was questioned for Eisenmenger patients who were 
frequently restricted from traveling in the past. A decrease in 
oxygen saturation because of the reduced cabin pressure was 
the major concern in these fragile patients who were advised 
to take supplementary oxygen or even to avoid air travels.  
  Aircrafts are pressurized to a cabin pressure altitude cor-
responding to a pressure at 1800 and 2400 m (6000 to 8000 
feet) above sea level. A Dutch group designed a unique study 
including cyanotic patients and healthy individuals and stud-
ied both groups during simulated and actual flights [44]. 
Commercial air travel was well tolerated. Actual decrease in 
oxygen saturation during ascent followed a similar pattern in 
patients and healthy controls and no patient experienced an 
adverse effects. A recently published retrospective study 
confirmed good tolerance of traveling in a commercial air-
craft and experiences of the Dutch study [45]. Patients with 
ES do not need to be advised against air travels and do not 
require in-flight nasal oxygen.  
Risk Reduction Strategie 
  Avoidance of travel and non-travel related stress (flight 
organization well in advance, easy transportation, 
avoidance of flying at busy periods; availability of lug-
gage carrier, wheelchair, etc.); 
  Avoidance of volume depletion (low humidity in com-
mercial aircrafts!); avoidance of alcoholic drinks; 
  Prevention of deep vein thrombosis with the potential 
of paradoxical emboli (business class travel, aisle seat, 
extension of the legs, periodic walks, fluid intake). 
Exposure to high altitude: Exposure to high altitude 
(>1500 m above sea level) may be safe. Indeed, Eisenmen-
ger patients traveled from Europe to Grand Canyon without 
adverse effects. However, a gradual ascent on land is impor-
tant and a time for acclimatization may be wise. In addition, 
a cable car or another transport medium should be available 
for an immediate descent in the case of health problems and 
an emergency. Exercise at high altitude must be very limited 
and strongly restricted by symptoms. 
1.10. Infective Endocarditis 
  Patients with ES carry a high risk for endocarditis with 
high morbidity and mortality. They require meticulous endo-
carditis prophylaxis [46, 47]. The importance of excellent 
oral hygiene must be emphasized to prevent endocarditis. 
1.11. Pregnancy and Contraception 
  In our view, ES is even today an absolute contraindica-
tion to pregnancy. In women with ES pregnancy is associ-
ated with a substantial risk for fetus and mother: as the sys-
temic vascular resistance drops during pregnancy, the right-
to-left shunt increases and the arterial oxygen saturation de-
creases. At particular risk are those patients who are already 
in a functional class III or IV. According to classic data 
spontaneous abortion occurs in up to 40%, premature deliv-
ery in 50%, and term delivery in only 25% of pregnancies 
[48, 49]. Moreover, 30% of the infants suffer from intrauter-
ine growth retardation and the perinatal mortality is also high 
(8% to 28%) [48, 49]. 
  Maternal mortality ranges from 30% to 60%, and may be 
attributed to syncope, thromboembolism, hypovolemia, he-
moptysis or preeclampsia [48, 49]. Most deaths occur either 
during delivery or within the first weeks after.  
  Although therapeutic abortion bears a risk, termination of 
pregnancy should be recommended because of the consider-
able maternal risk. Woman declining abortion need a 
multidisciplinary approach, including at least experienced 
congenital cardiologists, obstetricians, anesthetists, and neo-
natologists. In selected cases, nebulized Iloprost or intrave-
nous prostaglandin therapy may be indicated, even despite 
the lack of evidence and the unknown effects on the fetus 
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  Pregnant women with ES should be hospitalized after the 
20
th week of pregnancy - or earlier if clinical deterioration 
occurs.  
  In case of dyspnea, supplemental oxygen should be ad-
ministered, which may decrease the degree of PAH and 
right-to-left shunting to some degree. Congestive heart fail-
ure should be treated with digoxin and diuretics. The 
woman's fluid status, systemic arterial pressure and oxygen 
saturation should carefully be assessed.  
  The best mode of delivery is still a matter of discussion, 
and either vaginal delivery (with keeping the second stage of 
labor short by elective use of vacuum-assist delivery or for-
ceps delivery) or elective cesarean section are possible [50].  
  In any case, significant blood loss may induce arterial 
hypotension and increase the amount of the right-to-left 
shunt and cyanosis. Arterial hypotension should be treated 
immediately with parenteral volume replacement and vaso-
pressors. 
  Although no evidence based data exist, some centers use 
low-molecular weight heparin for thromboprophylaxis from 
the 20
th week of pregnancy. Prior to delivery, intravenous 
heparin (aPTT-controlled) can be started instead, as subcuta-
neous heparin can cause a persisting anticoagulatory effect. 
Low-molecular weight heparin can be reinstituted usually 1 
or 2 days after delivery, if the patient is stable. When heparin 
is administered too early after delivery, excessive bleeding, 
leading to maternal death, may occur.  
  Prevention of pregnancy and counseling about contracep-
tives is of outstanding importance. Best suitable contracep-
tion are the progestogen-only contraceptives without throm-
bophilic properties (pills, intrauterine devices, subdermal 
implantats), including progestogen-only pills (e.g. 
Cerazette
®), Mirena
® as an intrauterine system, Implanon
® as 
a subdermal implant or the subdermal injection of a proge-
stogen [51, 52].  
  As the ET-blocker Bosentan may reduce the efficacy of 
orally given progestogens due to enzyme induction, indi-
vidualized recommendations from an expert are mandatory 
in these special situations. The use of an intrauterine proge-
stogen coated coil might be a safe and efficient option, par-
ticularly, as the risk of a local infection and a consecutive 
endocarditis seem to be low.  
  Combined oral contraceptives are contraindicated be-
cause of the increased risk for thromboembolic complica-
tions associated with their use. Barrier methods, such as con-
doms and diaphragms, have an unacceptably high failure 
rate. Tubal ligation is an effective method of contraception, 
however, carrying a significant procedural risk itself.  
1.12. Non-Cardiac Surgery 
  Patients with ES are vulnerable to any hemodynamic 
changes and are at risk for any non-cardiac surgical proce-
dure. The increased pulmonary vascular resistance (Eisen-
menger physiology) precludes rapid adaptive mechanisms to 
any hemodynamic change caused by anesthetics, fluid shifts 
and/ or surgery [53, 54]. Every surgical procedure carries a 
high risk of morbidity and a substantial risk of mortality. No 
prospective study evaluated the risk of non-cardiac surgery 
in this population. 
  The perioperative risks include: 
  Increase in right-to-left shunt and increased cyanosis 
secondary to decrease in systemic vascular resistance 
leading to collapse and death; 
  Depression of ventricular function due to a sudden in-
crease in systemic vascular resistance; 
  Arrhythmias (supraventricular/ ventricular); 
  Risk of bleeding (hemostatic abnormalities); 
  Thromboembolic complications (thrombotic diathesis). 
Risk reduction strategies to reduce the perioperative risk 
[8]: 
  Meticulous preoperative evaluation (medical history, 
physical examination, ECG, chest x-ray, complete blood 
count, blood chemistry, coagulation parameters, Doppler 
echocardiography); 
  Provision of care by an expert team including cardiac 
anesthetist with expertise in the management of Eisen-
menger patients; 
  Local anesthesia whenever possible; 
  The choice of general anesthesia versus epidural-spinal 
anesthesia is controversial. General anesthesia is prefer-
able. Regional anesthesia may be hazardous as it results 
in sympathetic blockade and decrease in both afterload 
and preload; a bleeding diathesis is a contraindication to 
epidural/ spinal anesthesia; 
  Preoperative phlebotomy can be considered if the hema-
tocrit exceeds 65%. This strategy may increase platelet 
count and reduce the risk of intraoperative bleeding. The 
blood withdrawn should be reserved for autologous 
blood donation if required [53, 54]; 
  Careful intraoperative monitoring to detect sudden pres-
sure and volume changes, and pulse oximetry to assess 
oxygen saturation (changes in vascular resistance alters 
right-to-left shunting); 
  Surgery must be performed by an experienced surgeon; 
even a so-called simple surgical procedure (e.g. appen-
dectomy) is not simple, it is demanding for the entire 
team; 
  Endocarditis prophylaxis and  
  use of an air filter. 
  Eisenmenger patients are at risk for death even after the 
acute phase of the procedure; this implies that these patients 
need postoperative surveillance and should not be discharged 
too early. 
2. SURGICAL ASPECTS 
2.1. Pulmonary Artery Banding 
  Pulmonary artery banding for patients with Eisenmenger 
physiology was a matter of big debates in the late 1990s. 
Batista reported about a 19 year female with pulmonary ar-
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cular changes due to an atrial (ASD) and ventricular septal 
defect (VSD) [55]. Although there was increased right-to-left 
shunting, worsening of cyanosis was only transient after 
pulmonary artery banding. Cyanosis improved gradually, the 
patient was getting pink at rest and during exercise and un-
derwent successful closure of her ASD and VSD. The 
mechanism of this pulmonary vascular remodeling remains 
unclear. There is the hypothesis that decreased oxygen satu-
ration and lowered pulmonary artery pressure might have 
induced apoptosis and remodeling of the pulmonary vascular 
bed. Batista [55] performed the same surgical approach in 
six other patients with similar clinical response. This new 
concept, however, has remained experimental and is not per-
formed anymore. 
2.2. Transplantation 
  Transplantation is a final therapeutic option for patients 
with poor prognosis and quality of life. However, timing and 
appropriateness of transplantation remain difficult decisions 
in patients with ES. The following challenges have to be 
addressed before listing for transplantation: 
1)  Timing of listing is difficult because survival of Eisen-
menger patients is hard to predict and risk stratification 
scores established for patients with end-stage acquired 
heart disease do not apply to these patients. Survival of 
patients with ES is significantly better than in those with 
other forms of pulmonary arterial hypertension and their 
survival pattern cannot be compared between these two 
groups [30, 38, 56]. Median survival was 52.6 years in a 
population of 109 patients followed during 6.3 years 
[38]. Predictors of survival include: complexity of the 
underlying congenital heart defect, age at symptoms or 
referral to a tertiary care center, right heart failure symp-
toms, syncope, creatinine, atrial arrhythmias, function 
class, increased precordial ECG voltage as an index of 
RV hypertrophy, uric acid, high right atrial pressure [1, 
30, 38, 43, 57].  
2)  Eisenmenger patients have adapted to their limited 
working capacity since childhood and present often late 
to the transplant team. 
3)  Technical considerations are significant: complexity of 
the underlying anatomy, previous sternotomies and tho-
racotomies, major aorto-pulmonary or pleuro-pulmonary 
collaterals, risk of bleeding. Previous operative proce-
dures seem to have a negative impact on survival after 
transplantation and the existence of extensive pleuro-
pulmonary collateral vessels are considered a contrain-
dication for heart-lung transplantation [58]. 
4)  Heart-lung transplantation or bilateral lung transplanta-
tion/ single lung transplantation and repair of the con-
genital heart defect to increase the donor pool in the era 
of organ shortage? Single/ bilateral lung transplantation 
and repair of the congenital heart defect are attractive 
and may be feasible in patients with isolated defects 
(e.g. PDA, ASD, VSD). Bilateral lung transplantation 
and cardiac repair is a feasible option and can be per-
formed as an alternative procedure to heart-lung trans-
plantation in Eisenmenger patients without an increase 
in early or medium-term morbidity and mortality and re-
sults were comparable with heart-lung transplantation or 
with lung transplantations performed for other indica-
tions [59, 60]. However, another study showed a highly 
significant benefit of heart-lung transplantation over 
lung transplantation for patients with a VSD [61]. This 
is also consistent with another single center experience 
[58]. 
5)  The shortage of donor organs does have implications on 
the wait times for patients with CHD, which is longer 
than for other diagnostic groups. In addition, heart-lung 
transplantation is less attractive for transplant teams as 
the donor heart cannot be preserved for another recipi-
ent.  
  Transplantation in patients with ES must be performed in 
a tertiary care center with an established close collaboration 
between the transplant team and the CHD specialists 
(multidisciplinary team approach). Potential candidates for 
transplantation must be referred early to the transplant team 
as the question when to list an individual patient is hard to 
answer and the decision has to be made individually for 
every patient based on the medical history and the clinical 
presentation. The type of operation -heart-lung transplanta-
tion or double lung transplantation plus repair of the cardiac 
defect- depends on underlying CHD, co-morbidities and on 
the experiences of the transplant team. 
  Heart-lung transplantation can be a successful procedure 
for Eisenmenger patients with end-stage disease if the proce-
dure is performed by an experienced team [58, 61, 62]. One, 
5-year and 10-year survival ranges between 70% and 80%, 
50% and 70%, 30% and 50%, respectively [58, 61, 62]. 
Long-term complications and cause deaths include chronic 
rejection despite improved immunosuppressive therapy and 
infectious disease. 
  Transplantation remains a therapeutic option for selected 
patients and successful transplantation improves quality of 
life in severely disabled patients. However, patient selection 
and timing of listing for transplantation are critical and chal-
lenging, because Eisenmenger patients have very long natu-
ral survival patterns compared to patients with other forms of 
pulmonary hypertension. Potential candidates must be re-
ferred to a dedicated team sooner rather than later. 
3. LABORATORY PRECAUTIONS 
 Table  3 summarizes routine laboratory assessment of 
patients with cyanotic congenital heart disease (Table 3). 
Caution is required for accurate measurement of coagulation 
parameters, hematocrit and blood glucose. 
3.1. Coagulation Parameters 
  Frequently, physicians do not appreciate inaccurate 
measurements of coagulation parameters if blood is with-
drawn into regular tubes with a standard amount of citrate 
anticoagulant. Plasma volume is decreased in Eisenmenger 
patients due to secondary erythrocytosis and elevated hema-
tocrit. Thus, the amount of citrate anticoagulant is excessive 
for patients with cyanosis and secondary erythrocytosis. Ac-
curate measurement of coagulation factors requires adjust-
ment of the amount of liquid anticoagulants according to the 
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3.2. Hematocrit 
  Microhematocrit centrifugation results in plasma trapping 
and falsely raised hematocrit. Thus, determination of the 
hematocrit level must base on automated electronic particle 
counts. 
3.3. Blood Glucose 
  Reduced blood glucose levels are not uncommon in cya-
notic patients because of the increased in vitro glycolysis, 
which results from the increased number of red blood cells. 
Sodium fluoride must be added to the tube to prevent red cell 
glycolysis and artificial ‘hypoglycemia’. 
Table 3.  Routine Laboratory Assessment 
1) Hematology 
  Hemoglobin, hematocrit, white blood cell, platelets, red cell 
indices (MCV, MCHC); 
2) Iron stores 
  Ferritin, transferrin, transferrin saturation; 
3) Vitamines 
  Vitamine B12, folic acid in the presence of iron deficiency 
and normal or elevated MCV; 
4) Biochemistry 
  Creatinine, electrolytes, uric acid; 
5) Neurohormones 
  BNP or NT-pro-BNP; 
 
Table 4.  Risk Reduction Strategies 
  Avoidance of volume depletion; 
  Avoidance of iron deficiency (no routine phlebotomies); 
  Avoidance of cigarette smoking and recreational drug use; 
  Precaution or avoidance of drugs that impair renal function; 
  Use of an air filter for all intravenous lines to avoid air embo-
lism; 
  Avoidance of infectious disease:  
Annual flu shot, pneumovax 23, every 5 years; 
Prompt therapy of respiratory tract infections; 
  Avoidance of strenuous exercise/ stress (traveling). 
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